BiotechTube
Myosana Therapeutics

Myosana Therapeutics

San Diego, United States· Est.
myosanatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Myosana Therapeutics is an early-stage, privately held biotech focused on creating a transformative, non-viral gene delivery platform for genetic muscle diseases. The company has secured seed funding and strategic investments from patient advocacy groups to advance its lead programs. Its core strategy is to develop a targeted, muscle-specific delivery system that could expand the treatable disease landscape beyond the constraints of viral-based therapies.

Neuromuscular DiseasesCardiac Diseases

Technology Platform

Proprietary, muscle-targeted non-viral gene delivery platform designed to overcome limitations of viral vectors (e.g., immunogenicity, cargo size, re-dosing).

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The platform addresses a major bottleneck in gene therapy by enabling delivery of large genes and potential re-dosing, opening up a broad range of previously untreatable genetic muscle and heart diseases.
Strong validation and funding from leading patient advocacy groups (MDA, PPMD) provide credibility and direct patient community connections.

Risk Factors

High technical risk of achieving efficient, durable, and targeted gene delivery to muscle with a non-viral system.
Intense competition from advanced viral gene therapy programs and other modalities in its lead indications.
Limited capital runway necessitates a successful Series A raise in a challenging biotech financing environment.

Competitive Landscape

Myosana competes in the DMD and XLMTM spaces against established AAV gene therapy developers (e.g., Sarepta, Pfizer, Astellas) and other modality companies. Its primary differentiation is its non-viral platform, competing against other early-stage non-viral/gene editing companies. Success depends on demonstrating superior safety, efficacy, or dosing flexibility compared to viral approaches.

More companies in Cell & Gene Therapy →More companies in United States →